CV Therapeutics Inc. initiated a pivotal Phase III trial for CVT-3146, a candidate for use as a pharmacologic stress agent in cardiac perfusion imaging studies. (BioWorld Today)

Geron Adds $60M For Clinical Trials, Manufacturing Efforts

Oct. 30, 2003

By Kim Coghill

Geron Adds $60M For Clinical Trials, Manufacturing Efforts

Oct. 30, 2003

By Kim Coghill

CV Therapeutics Starts Phase III For CVT-3146, Waits On Ranexa

Oct. 30, 2003

By Kim Coghill

CV Therapeutics Inc. initiated a pivotal Phase III trial for CVT-3146, a candidate for use as a pharmacologic stress agent in cardiac perfusion imaging studies. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...